Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma businesswire.com August 3, 2026 at 7:00 AM ET ESLA The article reports on Estrella Immunopharma activating a new clinical site for its Phase I/II STARLIGHT-1 trial. This is a factual update on trial progress and does not inherently convey positive or negative sentiment about the company's stock performance.